Recent Price Movement and Market Context
On 2 Mar 2026, Alembic Pharmaceuticals opened sharply lower with a gap down of -5.7%, hitting an intraday low of Rs.671, which represents its lowest price point in the past year. This decline extends a five-day losing streak during which the stock has fallen by -9.77%. The day’s performance saw a further drop of -2.29%, underperforming the Pharmaceuticals & Biotechnology sector by -1.82%.
In contrast, the Sensex, despite opening 2,743.46 points lower, recovered by 1,260.44 points to trade at 79,804.17, down -1.82% on the day. The benchmark index remains below its 50-day moving average, though the 50DMA is positioned above the 200DMA, signalling mixed technical conditions in the broader market.
Technical Indicators and Moving Averages
Alembic Pharmaceuticals is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad weakness across short, medium, and long-term technical indicators highlights the prevailing bearish sentiment among market participants. The stock’s 52-week high stands at Rs.1,107.8, underscoring the extent of the recent decline.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Long-Term and Recent Financial Performance
Over the past year, Alembic Pharmaceuticals has generated a negative return of -7.24%, significantly lagging behind the Sensex’s positive 9.02% gain. The stock has also underperformed the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in maintaining competitive returns.
Operating profit growth has been subdued, with an annualised decline of -8.78% over the last five years. The company reported flat results in the December 2025 half-year period, reflecting limited momentum in earnings expansion. Quarterly earnings per share (EPS) have also been relatively low, with the most recent figure at Rs.6.77.
Balance Sheet and Efficiency Metrics
Inventory turnover ratio for the half-year stood at 2.79 times, which is on the lower side, suggesting slower inventory movement relative to peers. The debt-equity ratio remains modest at 0.28 times, indicating a conservative capital structure. The company’s ability to service debt is supported by a low Debt to EBITDA ratio of 0.90 times, reflecting manageable leverage levels.
Valuation and Profitability Indicators
Return on Capital Employed (ROCE) is reported at 12.6%, which is a positive indicator of capital efficiency. The enterprise value to capital employed ratio is 2.3, suggesting an attractive valuation relative to the company’s asset base. Despite the recent price weakness, Alembic Pharmaceuticals trades at a discount compared to the average historical valuations of its sector peers.
Profit growth over the past year has been recorded at 11.7%, which contrasts with the negative stock returns, resulting in a Price/Earnings to Growth (PEG) ratio of 1.8. This figure indicates that the market is pricing in slower growth prospects relative to earnings expansion.
Shareholding and Market Perception
Institutional investors hold a significant stake of 20.41% in Alembic Pharmaceuticals. These investors typically possess greater resources and analytical capabilities to assess company fundamentals, which may influence the stock’s trading dynamics and valuation.
Holding Alembic Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
To summarise, Alembic Pharmaceuticals Ltd. is currently trading at its lowest level in 52 weeks, with a price of Rs.671. The stock has experienced a consistent decline over the past five days, underperforming both its sector and the broader market. Financial indicators reveal subdued operating profit growth, flat recent results, and modest earnings per share. While the company maintains a conservative debt profile and demonstrates reasonable capital efficiency, valuation metrics reflect a discount relative to peers amid a challenging market environment.
Institutional holdings remain notable, suggesting continued interest from sophisticated investors despite the recent price weakness. The stock’s technical positioning below all major moving averages further emphasises the current downtrend.
Market Capitalisation and Mojo Ratings
Alembic Pharmaceuticals holds a Market Cap Grade of 3, reflecting its mid-tier capitalisation status within the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score stands at 37.0, with a recent downgrade from a Hold to a Sell rating on 25 Nov 2025. This rating change underscores the cautious stance adopted by rating agencies in light of the company’s recent performance and outlook.
Comparative Performance and Sector Context
Compared to the broader Pharmaceuticals & Biotechnology sector, Alembic Pharmaceuticals has underperformed, with the sector showing relative resilience. The stock’s 52-week high of Rs.1,107.8 contrasts sharply with the current price, highlighting the extent of the correction. The sector’s average valuations and performance metrics provide a benchmark against which Alembic’s current standing can be assessed.
Conclusion
The recent fall to a 52-week low at Rs.671 marks a significant milestone in Alembic Pharmaceuticals Ltd.’s stock price trajectory. The combination of subdued profit growth, flat recent results, and technical weakness has contributed to this decline. While the company maintains certain strengths such as low leverage and reasonable capital returns, the overall market response reflects a cautious appraisal of its near-term prospects and valuation.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
